Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A retrospective single-centre cohort study identifies BMI and dyslipidemia as associations with improved PFS in anti-PD-1-treated CRC, supported by exploratory lipidomic profiling, but lacks a control arm and prospective design to establish causation or clinical utility.
A narrative review synthesizing the state of knowledge on synthetic microbial communities as emerging biotherapeutics, establishing boundaries, mechanisms, and translational challenges without reporting primary experimental results.
This is a first-in-human, phase 1/2 trial registration with no results posted; the study is actively recruiting and designed to establish safety, tolerability, and initial antitumor activity of a novel pan-KRAS inhibitor.
This is a clinical trial registry record for an ongoing Phase 1 study with no results posted; the study is actively recruiting and outcome data are not yet available.
A single-centre mechanistic study in a rat model of chemotherapy toxicity using multi-omics; the design is sound but the evidence is preclinical and cannot directly support clinical practice without human trials.
This is a narrative review synthesizing existing knowledge about molecular pathways in colorectal cancer and therapeutic strategies, without presenting new primary data, clinical trials, or original findings to evaluate.
This is a narrative review synthesizing emerging evidence on the oral-gut axis and Peptostreptococcus in colorectal cancer, presenting mechanistic hypotheses and research perspectives rather than original empirical findings or definitive clinical evidence.
Preclinical organoid-based mouse model study demonstrating proof-of-concept for CD8+ T cell dysfunction characterization and ICI responsiveness, lacking direct clinical validation or comparative efficacy trials.